A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients - ZAP2.

Abstract

BACKGROUND:

Bisphosphonates are a class of drugs that slow bone loss and are a promising candidate to treat knee osteoarthritis (OA) patients. In a pilot study, we demonstrated that zoledronic acid reduced knee pain and size of subchondral bone marrow lesions (BMLs) over 6 months in knee OA patients with significant knee pain and BMLs. A longer, larger study is required to assess whether decreases in BML size will translate to reductions in cartilage loss over time. We are currently conducting a multicentre, randomised, double-blind, placebo-controlled trial over 24 months that aims to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change (assessed using magnetic resonance imaging (MRI)) and knee pain in knee OA patients.

METHODS:

Two hundred sixty-four patients with clinical knee OA, significant knee pain and subchondral BMLs present on MRI will be recruited in Hobart, Melbourne, Sydney and Adelaide. They will be randomly allocated to the two arms of the study, receiving an annual identical intravenous infusion of either 100 mL of fluid containing zoledronic acid (5 mg/100 mL) or placebo (0.9% NaCl 100 mL), at baseline and 1 year later. MRI of the study knee will be performed at screening, month 6 and 24. Knee structure, symptoms and function will be assessed using validated methods. The primary outcome is absolute change in tibiofemoral cartilage volume (mm3) over 24 months. Secondary outcomes include improvement in knee pain over 3, 6, 12, 18, and 24 months and reductions in BML size over 6 and 24 months. The primary analyses will be intention-to-treat analyses of primary and secondary outcomes. Per protocol analyses will be performed as the secondary analyses.

DISCUSSION:

This study will provide high-quality evidence to assess whether zoledronic acid has a novel disease modifying effect in OA by slowing cartilage loss and reducing pain. If zoledronic acid proves effective, it suggests great potential for cost savings through a delay or reduced need for joint replacement surgery, and potential for great improvements in quality of life for OA suffers.

TRIAL REGISTRATION:

Australian New Zealand Clinical Trials Registry: ACTRN12613000039785 , registered on 14 January 2013.

• Authors: Dawn Aitken, Laura L Laslett, Guoqi Cai, Catherine Hill, Lyn March, Anita E Wluka, Yuanyuan Wang, Leigh Blizzard, Flavia Cicuttini, Graeme Jones
• Journal: BMC musculoskeletal disorders (BMC Musculoskelet Disord) Vol. 19 Issue 1 Pg. 217 (Jul 18 2018) ISSN: 1471-2474 [Electronic] England
• PMID: 30021646 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Bone Density Conservation Agents
• Zoledronic Acid

Topics

• Aged
• Aged, 80 and over
• Bone Density Conservation Agents (administration & dosage)
• Double-Blind Method
• Drug Administration Schedule
• Female
• Humans
• Infusions, Intravenous
• Knee Joint (diagnostic imaging, drug effects)
• Male
• Middle Aged
• Osteoarthritis, Knee (diagnostic imaging, drug therapy)
• Pain (diagnostic imaging, drug therapy)
• Time Factors
• Treatment Outcome
• Zoledronic Acid (administration & dosage)